Research indicates that the investigational medicine (a medicine not approved for clinical use) evaluated in the evoke studies might be beneficial against mild cognitive impairment or early Alzheimer’s disease. It is not yet approved for the treatment of Alzheimer’s disease. The evoke studies will evaluate if the investigational medicine, which comes in the form of a small tablet that is taken orally, is safe and effective for the treatment of mild cognitive impairment or early Alzheimer’s disease.